Treatment with Trichostatin A (TSA), a well-known histone deacetylase (HDAC) inhibitor, was able to restore DAB2 expression in nasopharyngeal carcinoma, squamous cell carcinoma, and transitional carcinoma cells [47], indicating that HDAC-mediated chromatin modulation may play a role in DAB2 downregulation [48]. This evidence concerns the gene HDAC9 and transitional cell carcinoma.